Recent Updates
Recently added Catalysts
INCY Positive Sentiment

Incyte to Present at Upcoming Investor Conferences

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Incyte announced its participation in several investor conferences in November 2026. The company will present at the Wolfe Research Healthcare Conference, Jefferies Global Healthcare Conference, and UBS Global Biopharma Conference. Live webcasts of the presentations will be available for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Incyte will present at multiple investor conferences.
  • Webcasts will be available for live access.
  • The conferences are scheduled for November 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+31%
120-day peak, hindsight
Typical move
2.1%
average across 15 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
INCA33890
Phase 3 · CRC (Colorectal Cancer)

Full Press Release Details

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST) Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT) UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 1:20 pm (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and wi

Frequently Asked Questions

When will Incyte present at investor conferences?

Incyte will present at investor conferences in November 2026.

Which conferences will Incyte attend?

Incyte will attend Wolfe Research, Jefferies, and UBS conferences.

Will the presentations be available online?

Yes, the presentations will be webcast live.

What are the dates of the conferences?

The conferences are on November 10 and 17, 2026.

ShareAdd on Google
Tags: INCY Incyte investor conferences Wolfe Research Jefferies UBS
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$3855M liquidity · $225M/mo burn
~17 mo
Low dilution risk
Lead asset
INCA33890Phase 3
CRC (Colorectal Cancer) →

Catalyst track record

+31%
best trade around INCY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for INCY.

See every catalyst's timing & PoA →